D M Evon1, J Amador2, P Stewart2, B B Reeve3, A S Lok4, R K Sterling5, A M Di Bisceglie6, N Reau7, M Serper8, S Sarkar9, J K Lim10, C E Golin11,12, M W Fried1. 1. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, USA. 2. Department of Biostatistics, University of North Carolina, Chapel Hill, USA. 3. Department of Population Health Sciences, Duke University, Durham, USA. 4. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, USA. 5. Division of Gastroenterology, Hepatology, and Nutrition Virginia Commonwealth University, Richmond, USA. 6. Department of Internal Medicine, Saint Louis University, St Louis, USA. 7. Department of Internal Medicine, Rush Medical Center, Chicago, USA. 8. Department of Medicine, University of Pennsylvania, Philadelphia, USA. 9. Department of Internal Medicine, University of California, Davis, USA. 10. Department of Internal Medicine, Yale University, New Haven, USA. 11. Division of General Medicine and Clinical Epidemiology, University of North Carolina, Chapel Hill, USA. 12. Department of Health Behavior, University of North Carolina, Chapel Hill, USA.
Abstract
BACKGROUND: To better understand symptoms experienced by patients infected with chronic hepatitis C virus (HCV), valid and reliable patient-reported outcome (PRO) measures are needed. AIM: To assess the reliability and validity of 10 patient-reported outcomes measurement information system (PROMIS) measures and the Headache Impact Test-6 (HIT-6) in a large national sample of patients with HCV. METHODS: Pre-treatment data from 961 patients with HCV starting direct acting antiviral therapy at 11 U.S. liver centers were analyzed. Internal reliability was evaluated using Cronbach's alpha coefficient; frequency distributions were examined for floor and ceiling effects; structural validity was investigated via item-response-theory models; convergent validity was evaluated using correlations with theoretically-similar items from the HCV-PRO and memorial symptom assessment scale (MSAS); and known-groups validity was investigated by observing PRO differences by liver disease status and number of comorbidities. RESULTS: The HIT-6 and the majority of the PROMIS measures yielded excellent reliability (alphas ≥ 0.87). Ceiling effects were infrequent ( < 4%), while 30%-59% of patients reported no symptoms (floor effects). The data supported structural validity of the HIT-6 and most PROMIS measures. The PROMIS measures showed moderate to strong correlations with theoretically-similar items from the HCV-PRO and MSAS (0.39-0.77). Trends were observed between worse PRO scores and advanced cirrhosis and greater number of comorbidities, lending support for known-groups validity. CONCLUSIONS: The psychometric properties of the HIT-6 and PROMIS measures performed satisfactorily in this large cohort of patients with HCV starting direct acting antiviral therapy. Opportunities exist for further refinement of these PROs. Evaluation of performance over time and in under-represented subgroups is needed.
BACKGROUND: To better understand symptoms experienced by patients infected with chronic hepatitis C virus (HCV), valid and reliable patient-reported outcome (PRO) measures are needed. AIM: To assess the reliability and validity of 10 patient-reported outcomes measurement information system (PROMIS) measures and the Headache Impact Test-6 (HIT-6) in a large national sample of patients with HCV. METHODS: Pre-treatment data from 961 patients with HCV starting direct acting antiviral therapy at 11 U.S. liver centers were analyzed. Internal reliability was evaluated using Cronbach's alpha coefficient; frequency distributions were examined for floor and ceiling effects; structural validity was investigated via item-response-theory models; convergent validity was evaluated using correlations with theoretically-similar items from the HCV-PRO and memorial symptom assessment scale (MSAS); and known-groups validity was investigated by observing PRO differences by liver disease status and number of comorbidities. RESULTS: The HIT-6 and the majority of the PROMIS measures yielded excellent reliability (alphas ≥ 0.87). Ceiling effects were infrequent ( < 4%), while 30%-59% of patients reported no symptoms (floor effects). The data supported structural validity of the HIT-6 and most PROMIS measures. The PROMIS measures showed moderate to strong correlations with theoretically-similar items from the HCV-PRO and MSAS (0.39-0.77). Trends were observed between worse PRO scores and advanced cirrhosis and greater number of comorbidities, lending support for known-groups validity. CONCLUSIONS: The psychometric properties of the HIT-6 and PROMIS measures performed satisfactorily in this large cohort of patients with HCV starting direct acting antiviral therapy. Opportunities exist for further refinement of these PROs. Evaluation of performance over time and in under-represented subgroups is needed.
Authors: Augustine C Lee; Jeffrey B Driban; Lori Lyn Price; William F Harvey; Angie Mae Rodday; Chenchen Wang Journal: J Pain Date: 2017-05-10 Impact factor: 5.820
Authors: Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch Journal: J Hepatol Date: 2006-11-27 Impact factor: 25.083
Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Dinesh Khanna; Ron D Hays; Andrew B Shreiner; Gil Y Melmed; Lin Chang; Puja P Khanna; Roger Bolus; Cynthia Whitman; Sylvia H Paz; Tonya Hays; Steven P Reise; Brennan Spiegel Journal: Dig Dis Sci Date: 2017-03-01 Impact factor: 3.199
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Victor T Chang; Shirley S Hwang; Howard T Thaler; Basil S Kasimis; Russell K Portenoy Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2004-04 Impact factor: 2.217
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Marina Serper; Donna M Evon; Paul W Stewart; Anna S Lok; Jipcy Amador; Bryce B Reeve; Carol E Golin; Michael W Fried; K Rajender Reddy; Richard K Sterling; Souvik Sarkar; Adrian M Di Bisceglie; Joseph K Lim; David R Nelson; Nancy Reau Journal: J Gen Intern Med Date: 2019-10-28 Impact factor: 5.128
Authors: Donna M Evon; Souvik Sarkar; Jipcy Amador; Anna S Lok; Richard K Sterling; Paul W Stewart; Bryce B Reeve; Marina Serper; Nancy Reau; K Rajender Reddy; Adrian M Di Bisceglie; David R Nelson; Carol E Golin; Joseph K Lim; Michael W Fried Journal: J Hepatol Date: 2019-05-13 Impact factor: 30.083
Authors: Marina Serper; Donna M Evon; Jipcy Amador; Paul W Stewart; Souvik Sarkar; Anna S Lok; Richard K Sterling; Bryce B Reeve; Carol E Golin; K Rajender Reddy; Joseph K Lim; Nancy Reau; David R Nelson; Adrian M Di Bisceglie; Michael W Fried Journal: Liver Int Date: 2021-01-22 Impact factor: 5.828